var data={"title":"Cytarabine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Cytarabine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5967?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">see &quot;Cytarabine: Drug information&quot;</a> and <a href=\"topic.htm?path=cytarabine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Cytarabine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708668\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Experienced physician: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-4em;margin-left:4em;\">Only physicians experienced in cancer chemotherapy should use cytarabine.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Drug toxicities:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">For induction therapy, patients should be treated in a facility with laboratory and supportive resources sufficient to monitor drug tolerance and protect and maintain a patient compromised by drug toxicity. The main toxic effect of cytarabine is bone marrow suppression with leukopenia, thrombocytopenia, and anemia. Less serious toxicity includes nausea, vomiting, diarrhea and abdominal pain, oral ulceration, and hepatic dysfunction.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">The physician must judge possible benefit to the patient against known toxic effects of this drug in considering the advisability of therapy with cytarabine. Before making this judgment or beginning treatment, the physician should be familiar with the following text.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155998\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Cytarabine Injection;</li>\n      <li>Cytosar</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046767\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Antimetabolite</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046759\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">see &quot;Cytarabine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dosing and frequency may vary by protocol and/or treatment phase; refer to specific protocol.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> In pediatric patients, IV dosing may be based on either BSA (mg/m<sup>2</sup>) or weight (mg/kg); use extra precaution to verify dosing parameters during calculations. Intrathecal dosing is based on the age of the patient.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Emetogenic potential dependent on dose: Doses &le;200 mg/m<sup>2</sup> are associated with a low emetic potential, doses &gt;200 mg/m<sup>2 </sup>to &lt;3,000 mg/m<sup>2</sup> are associated with a moderate emetic potential and doses &ge;3,000 mg/m<sup>2</sup> are associated with a high emetic potential (Dupuis 2011); antiemetics are recommended to prevent nausea and vomiting in all cases</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute</b>\n      <b> lymphocytic leukemia, B-cell (B-ALL):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i> High risk B-ALL: </i> Limited data available, multiple regimens reported:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Larsen 2016: Consolidation and delayed intensification I and II: Children 1 to 9 years: IV, SubQ: 75 mg/m<sup>2</sup> over 1 to 30 minutes or subcutaneous once daily for 4 days every 7 days for 2 courses; specific days depends on protocol phase</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Steinherz 1993: NYII Protocol: Consolidation: Children and Adolescents: IV: 3,000 mg/m<sup>2</sup> over 3 hours for 4 doses on Days 28, 29, 35, and 36; experts at some centers have suggested fewer doses (eg, 2 doses)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i> Isolated CNS; relapse: </i>Limited data available; multiple regimens reported: Infants, Children, and Adolescents: IV: 300 mg/m<sup>2</sup>/dose; frequency dependent upon protocol</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Ribeiro 1995, Rivera 1996: Children and Adolescents &le;14 years: Induction: Administer on Days 8, 22, 36; for Maintenance administer every 5 weeks for 52 weeks in combination with teniposide</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Winick 1993: Continuation therapy: Infants, Children, and Adolescents: Administer on day 1 and 4 of week 7, 14, 21, 28, 35, 42, 49, and 56 in conjunction with teniposide</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute myeloid leukemia (AML):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>\n        <i>Remission induction: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Manufacturer's labeling: Infants, Children, and Adolescents: IV: Standard dose: 100 mg/m<sup>2</sup>/day continuous infusion for 7 days or 200 mg/m<sup>2</sup>/day continuous infusion (as 100 mg/m<sup>2</sup>/dose over 12 hours every 12 hours) for 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Alternate dosing: Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">ADE regimen (Gamis 2014): <b>Note:</b> Some aspects of protocol dosing based on previous reports (Cooper 2012; Gibson 2011; Guest 2014; Woods 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Induction 1 ADE (10 + 3 + 5) and Induction 2 ADE (8 + 3 + 5):</p>\n    <p style=\"text-indent:-2em;margin-left:14em;\">Infants and Children with BSA &lt;0.6 m<sup>2</sup>: IV: 3.3 mg/<b>kg </b>over 1 to 30 minutes every 12 hours for 10 days (induction 1) or 8 days (induction 2) in combination with daunorubicin and etoposide</p>\n    <p style=\"text-indent:-2em;margin-left:14em;\">Children and Adolescents with BSA &ge;0.6 m<sup>2</sup>: IV: 100 mg/m<sup>2</sup> over 1 to 30 minutes every 12 hours for 10 days (induction 1) or 8 days (induction 2) in combination with daunorubicin and etoposide</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">7 + 3 regimen (Woods 1990):</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Infants and Children &lt;3 years: IV: 3.3 mg/<b>kg</b>/day continuous infusion for 7 days; minimum of 2 courses (in combination with daunorubicin)</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Children &ge;3 years and Adolescents: IV: 100 mg/m<sup>2</sup>/day continuous infusion for 7 days; minimum of 2 courses (in combination with daunorubicin)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>\n        <i>Intensification: </i></b>Limited data available (Gamis 2014): <b>Note:</b> Some aspects of protocol dosing based on previous reports (Cooper 2012; Gibson 2011; Guest 2014; Woods 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Intensification 1: AE therapy</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants and Children with BSA &lt;0.6 m<sup>2</sup>: IV: 33 mg/<b>kg</b> over 1 hour every 12 hours for 5 days (in combination with etoposide)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children and Adolescents with BSA &ge;0.6 m<sup>2</sup>: IV: 1,000 mg/m<sup>2</sup> over 1 hour every 12 hours for 5 days (in combination with etoposide)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Intensification 2 (for patients not undergoing stem cell transplant): MA therapy:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants and Children with BSA &lt;0.6 m<sup>2</sup>: IV: 33 mg/<b>kg</b> over 1 hour every 12 hours for 4 days (in combination with mitoxantrone)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children and Adolescents with &ge;0.6 m<sup>2</sup>: IV: 1,000 mg/m<sup>2</sup> over 1 hour every 12 hours for 4 days (in combination with mitoxantrone)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Intensification 3 (for patients not undergoing stem cell transplant):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants and Children with BSA &lt;0.6 m<sup>2</sup>: IV: 99 mg/<b>kg</b> every 12 hours on days 1, 2, 8 and 9 in combination with <i>E. coli</i> L-asparaginase; <b>Note:</b> Some centers have substituted Erwinia asparaginase due to <i>E. coli</i> L-Asparaginase no longer being available.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children and Adolescents with BSA &ge;0.6 m<sup>2</sup>: IV: 3,000 mg/m<sup>2</sup> every 12 hours on Days 1, 2, 8, and 9 in combination with <i>E. coli</i> L-asparaginase; <b>Note: </b>Some centers have substituted Erwinia asparaginase due to <i>E. coli</i> L-Asparaginase no longer being available.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>\n        <b>Consolidation or refractory disease:</b></i> Capizzi II regimen (high-dose cytarabine [fixed]): Children &ge;6 years and Adolescents: IV: 3,000 mg/m<sup>2</sup> over 3 hours every 12 hours for 4 doses, followed by <i>E. coli</i> L-Asparaginase (some centers have substituted<i> Erwinia asparaginase</i> due to <i>E. coli</i> L-Asparaginase no longer being available) 6 hours after the last dose of cytarabine (Capizzi 1984)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>\n        <i>Salvage treatment for refractory/recurrent disease:</i></b> Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Clofarabine/cytarabine regimen: Children and Adolescents: IV: 1,000 mg/m<sup>2</sup> over 2 hours once daily for 5 days (in combination with clofarabine; administer cytarabine 4 hours after initiation of clofarabine) for up to 2 induction cycles (Cooper 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">FLAG regimen: Children &ge;11 years and Adolescents: IV: 2,000 mg/m<sup>2</sup> over 4 hours once daily for 5 days (in combination with fludarabine and G-CSF); may repeat once if needed (Montillo 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">MEC regimen:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Children &ge;5 years and Adolescents: IV: 1,000 mg/m<sup>2</sup> over 6 hours for 6 days (in combination with etoposide and mitoxantrone) (Amadori 1991)</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Adolescents &ge;15 years: IV: 500 mg/m<sup>2</sup>/day continuous infusion days 1, 2, and 3 and days 8, 9, and 10 (in combination with mitoxantrone and etoposide); may administer a second course if needed (Archimbaud 1991; Archimbaud 1995)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Non-Hodgkin lymphomas:</b> Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i> Intermediate-risk B-cell NHL (Group B)</i>: Consolidation<i>:</i> R-CYM 1 and 2 regimen (Goldman 2013; Patte 2007): Children and Adolescents: IV: 100 mg/m<sup>2</sup>/day as a continuous infusion over 24 hours on Days 2 through 6 (5 days; total dose: 500 mg/m<sup>2 </sup>as a 120-hour infusion) (in combination with rituximab and methotrexate)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>High-risk B-cell NHL (Group C):</i> Consolidation: R-CYVE 1 and 2 regimen (Cairo 2007; Patte 2001): Infants &ge;6 months, Children, and Adolescents: IV: 50 mg/m<sup>2 </sup>infused over 12 hours (2000 to 0800) for 5 doses (Days 1 to 5); follow each 12-hour infusion dose with 3,000 mg/m<sup>2</sup> infused over 3 hours which starts at the end of the 12-hour infusion (0800 - 1100) x 5 doses (days 2 to 6) in combination with etoposide</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>B-lineage lymphoblastic lymphoma (B-LLy)</i> (Termuhlen 2013):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Consolidation phase: Children and Adolescents: IV, SubQ: 75 mg/m<sup>2</sup> once daily for 4 days every 7 days for 4 courses (Days 0 to 3, 7 to 10, 14 to 17, 21 to 24)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Delayed intensification: Children and Adolescents: IV, SubQ: 75 mg/m<sup>2</sup> once daily for 4 days every 7 days for 2 courses (Days 35 to 38 and 42 to 45)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Meningeal leukemia:</b> Infants, Children, and Adolescents: <b>Note: </b> Optimal intrathecal chemotherapy dosing should be based on age (see following information) rather than on body surface area (BSA); CSF volume correlates with age and not to BSA (Bleyer 1983; Kerr 2001).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling (based on BSA): Intrathecal: 30 mg/m<sup>2</sup> every 4 days; range: 5 to 75 mg/m<sup>2</sup> once daily for 4 days or once every 4 days until CNS findings normalize, followed by one additional treatment</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing: Age-based intrathecal dosing: Intrathecal:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>CNS prophylaxis (AML)</i> (Woods 1990):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&lt;1 years: 20 mg per dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">1 to &lt;2 years: 30 mg per dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">2 to &lt;3 years: 50 mg per dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ge;3 years: 70 mg per dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>CNS prophylaxis (ALL):</i> Dosing regimens variable, age-specific regimens reported from literature:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Gaynon 1993: Administer on day 0 of induction therapy: Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&lt;2 years: 30 mg per dose</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">2 to &lt;3 years: 50 mg per dose</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&ge;3 years: 70 mg per dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Pieters 2007: Administer on day 15 of induction therapy, days 1 and 15 of reinduction phase; and day 1 of cycle 2 of maintenance 1A phase: Infants and young Children (&le;12 months at enrollment):</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&lt;1 year: 15 mg per dose</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&ge;1 years: 20 mg per dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Lin 2008: Administer as part of triple intrathecal therapy (TIT) on days 1 and 15 of induction therapy; days 1, 15, 50, and 64 (standard risk patients) or days 1, 15, 29, and 43 (high-risk patients) during consolidation therapy; day 1 of reinduction therapy, and during maintenance therapy (very high-risk patients receive on days 1, 22, 45, and 59 of induction, days 8, 22, 36, and 50 of consolidation therapy, days 8 and 38 of reinduction therapy, and during maintenance): Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&lt;1 year: 18 mg per dose</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">1 to &lt;2 years: 24 mg per dose</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">2 to &lt;3 years: 30 mg per dose</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&gt;3 years: 36 mg per dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Treatment, CNS leukemia (ALL), Very high-risk:</i> Administer as part of triple intrathecal therapy (TIT) weekly until CSF remission, then every 4 weeks throughout continuation treatment (Lin 2008): Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&lt;1 year: 18 mg per dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">1 to &lt;2 years: 24 mg per dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">2 to &lt;3 years: 30 mg per dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ge;3 years: 36 mg per dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Note:</b> Doses &gt;1,000 mg/m<sup>2</sup> are associated with a moderate emetic potential in adults (Basch 2011; Roila 2010); antiemetics are recommended to prevent nausea and vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute myeloid leukemia (AML) remission induction:</b> IV: 100 mg/m<sup>2</sup>/day continuous infusion for 7 days or 200 mg/m<sup>2</sup>/day continuous infusion (as 100 mg/m<sup>2</sup> over 12 hours every 12 hours) for 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Meningeal leukemia:</b> Intrathecal: 30 mg/m<sup>2</sup> every 4 days; range: 5 to 75 mg/m<sup>2</sup> once daily for 4 days or once every 4 days until CNS findings normalize, followed by 1 additional treatment. <b>Note:</b> Optimal intrathecal chemotherapy dosing should be based on age rather than on body surface area (BSA); CSF volume correlates with age and not to BSA (Bleyer 1983; Kerr 2001).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> IV: There are no dosage adjustments provided in the manufacturer's labeling; however, the following guidelines have been used by some clinicians:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: Standard dosing range (100 to 200 mg/m<sup>2</sup>): No adjustment necessary (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Aronoff 2007: Standard dosing range of 100 to 200 mg/m<sup>2</sup>: No adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Kintzel 1995: High-dose cytarabine 1,000 to 3,000 mg/m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 46 to 60 mL/minute: Administer 60% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 31 to 45 mL/minute: Administer 50% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;30 mL/minute: Consider use of alternative drug</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Smith 1997: High-dose cytarabine &ge;2,000 mg/m<sup>2</sup>/dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Serum creatinine 1.5 to 1.9 mg/dL or increase (from baseline) of 0.5 to 1.2 mg/dL: Reduce dose to 1,000 mg/m<sup>2</sup>/dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Serum creatinine &ge;2 mg/dL or increase (from baseline) of &gt;1.2 mg/dL: Reduce dose to 100 mg/m<sup>2</sup>/day as a continuous infusion</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis: In 4-hour dialysis sessions (with high flow polysulfone membrane) 6 hours after cytarabine 1,000 mg/m<sup>2</sup> over 2 hours, 63% of the metabolite, ARA-U was extracted from plasma (based in a single adult case report) (Radeski 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> IV: Dose may need to be adjusted in patients with liver failure since cytarabine is partially detoxified in the liver. There are no dosage adjustments provided in the manufacturer's labeling; however, the following guidelines have been used by some clinicians: All patients:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Floyd 2006: Transaminases (any elevation): Administer 50% of dose; may increase subsequent doses in the absence of toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Koren 1992 (dose not specified): Bilirubin &gt;2 mg/dL: Administer 50% of dose; may increase subsequent doses in the absence of toxicity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155976\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 20 mg/mL (25 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 20 mg/mL (5 mL, 50 mL); 100 mg/mL (20 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg (1 ea); 500 mg (1 ea); 1 g (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155961\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046771\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: <b>Note:</b> In pediatric patients, IV doses &le;200 mg/m2 are associated with a low emetic potential, doses &gt;200 to &lt;3,000 mg/m<sup>2</sup> are associated with a moderate emetic potential and doses &ge;3,000 mg/m<sup>2</sup> are associated with a high emetic potential (Dupuis 2013); antiemetics are recommended to prevent nausea and vomiting in all cases. In adults, doses &gt;1,000 mg/m<sup>2</sup> are associated with a moderate emetic potential (Basch 2011; Roila 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV infusion: May infuse as a continuous infusion over several hours (eg, 12 to 24 hours has been reported in pediatric trials) (Cairo 2007; Patte 2001). The manufacturer suggests continuous infusion of standard dose: 100 to 200 mg/m<sup>2</sup>/day. High-dose cytarabine has been infused over 1 to 3 hours according to protocols (refer to protocol) (Capizzi 1984).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IVP: Administration over 15 to 30 minutes; has been reported in pediatric trials</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Subcutaneous: May administer at concentration not to exceed 100 mg/mL (Allwood 2002); rotate injection sites; some centers have used thigh, abdomen, and flank regions</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intrathecal administration: Antiemetic therapy should be administered prior to intrathecal doses of cytarabine. Administer as soon as possible after preparation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49130965\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).   </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155991\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Store intact vials of powder for reconstitution at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); store intact vials of solution at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IV: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Powder for reconstitution: Reconstituted solutions should be stored at room temperature and used within 48 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">For IV infusion: Solutions for IV infusion diluted in D<sub>5</sub>W or NS are stable for 8 days at room temperature, although the manufacturer recommends administration as soon as possible after preparation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Intrathecal: Administer as soon as possible after preparation. After preparation, store intrathecal medications in an isolated location or container clearly marked with a label identifying as &quot;intrathecal&quot; use only.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046770\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Remission induction in acute myeloid leukemia (AML), treatment of acute lymphocytic leukemia (ALL) and chronic myelocytic leukemia (CML; blast phase) (FDA approved in pediatric patients [age not specified] and adults); has also been used in AML consolidation treatment, AML salvage treatment, and treatment of non-Hodgkin lymphomas (NHL) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intrathecal: Prophylaxis and treatment of meningeal leukemia (FDA approved in pediatric patients [age not specified] and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156059\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cytarabine may be confused with clofarabine, Cytosar, Cytoxan, vidarabine</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cytarabine (conventional) may be confused with cytarabine liposomal</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cytarabine (conventional) (100 mg/5 mL; Hospira manufacturer) may be confused with vinorelbine (50 mg/5 mL; Hospira manufacturer) due to similar packaging; potential for inadvertent intrathecal administration of vinorelbine may occur (ISMP, [Smetzer 2015]).</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cytosar-U may be confused with cytarabine, Cytovene, Cytoxan, Neosar</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drugs classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n          <i>Intrathecal medication safety:</i> The American Society of Clinical Oncology (ASCO)/Oncology Nursing Society (ONS) chemotherapy administration safety standards (Jacobson, 2009) encourage the following safety measures for intrathecal chemotherapy:</p>\n        <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">&bull; Intrathecal medication should not be prepared during the preparation of any other agents</p>\n        <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">&bull; After preparation, store in an isolated location or container clearly marked with a label identifying as &quot;intrathecal&quot; use only</p>\n        <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">&bull; Delivery to the patient should only be with other medications also intended for administration into the central nervous system</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156055\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">CNS, gastrointestinal, ophthalmic, and pulmonary toxicities are more common with high-dose regimens.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Angina pectoris, chest pain, local thrombophlebitis, pericarditis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Aseptic meningitis, cerebral dysfunction, dizziness, headache, neuritis, neurotoxicity, paralysis (intrathecal and IV combination therapy), reversible posterior leukoencephalopathy syndrome</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Acute generalized exanthematous pustulosis, alopecia, dermal ulcer, ephelis, pruritus, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hyperuricemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, anal fissure, anorexia, diarrhea, esophageal ulcer, esophagitis, increased serum amylase, increased serum lipase, intestinal necrosis, mucositis, nausea, pancreatitis, sore throat, toxic megacolon, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Urinary retention</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, bone marrow depression, hemorrhage, leukopenia, megaloblastic anemia, neutropenia (onset: 1 to 7 days; nadir [biphasic]: 7 to 9 days and at 15 to 24 days; recovery [biphasic]: 9 to 12 days and at 24 to 34 days), reticulocytopenia, thrombocytopenia (onset: 5 days; nadir: 12 to 15 days; recovery 15 to 25 days)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatic insufficiency, hepatic sinusoidal obstruction syndrome (formerly known as hepatic veno-occlusive disease), increased serum transaminases (acute), jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Allergic edema, anaphylaxis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Sepsis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Cellulitis at injection site, inflammation at injection site (SC injection), local inflammation (anus), pain at injection site (SC injection)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Rhabdomyolysis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Conjunctivitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Renal insufficiency</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Acute respiratory distress, dyspnea, interstitial pneumonitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Drug toxicity (cytarabine syndrome; chest pain, conjunctivitis, fever, maculopapular rash, malaise, myalgia, ostealgia), fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Adverse events associated with high-dose cytarabine</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Cardiomegaly, cardiomyopathy (in combination with cyclophosphamide)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Coma, drowsiness, neurocerebellar toxicity, neurotoxicity (patients with renal impairment), peripheral neuropathy (motor and sensory), personality changes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Alopecia (complete), desquamation, skin rash (severe)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Gastrointestinal ulcer, necrotizing enterocolitis, pancreatitis, peritonitis, pneumatosis cystoides intestinalis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Hepatic abscess, hepatic injury, hyperbilirubinemia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Sepsis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Corneal toxicity, hemorrhagic conjunctivitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Acute respiratory distress, pulmonary edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Adverse events associated with intrathecal cytarabine administration</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Aphonia, leukoencephalopathy (necrotizing; with concurrent cranial irradiation, intrathecal methotrexate, and intrathecal hydrocortisone), nerve palsy (accessory nerve), neurotoxicity, paraplegia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dysphagia, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blindness (with concurrent systemic chemotherapy and cranial irradiation), diplopia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough, hoarseness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155982\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to cytarabine or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155965\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: <b>[US Boxed Warning]: Myelosuppression (leukopenia, thrombocytopenia and anemia) is the major toxicity of cytarabine.</b> Use with caution in patients with prior drug-induced bone marrow suppression. Monitor blood counts frequently; once blasts are no longer apparent in the peripheral blood, bone marrow should be monitored frequently. Monitor for signs of infection or neutropenic fever due to neutropenia or bleeding due to thrombocytopenia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cytarabine syndrome: Cytarabine (ARA-C) syndrome is characterized by fever, myalgia, bone pain, chest pain (occasionally), maculopapular rash, conjunctivitis, and malaise; generally occurs 6 to 12 hours following administration. May be managed with corticosteroids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal toxicities:<b> [US Boxed Warning]: Toxicities (less serious) include nausea, vomiting, diarrhea, abdominal pain, oral ulcerations and hepatic dysfunction.</b> In adults, doses &gt;1000 mg/m<sup>2</sup> are associated with a moderate emetic potential (Hesketh 2017; Roila 2016). In pediatrics, doses &gt;200 mg/m<sup>2</sup> are associated with a moderate emetic potential and 3000 mg/m<sup>2</sup> is associated with a high emetic potential (Dupuis 2011); antiemetics are recommended to prevent nausea and vomiting.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Anaphylaxis resulting in acute cardiopulmonary arrest has been reported (rare).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pancreatitis: There have been reports of acute pancreatitis in patients receiving continuous infusion cytarabine and in patients receiving cytarabine who were previously treated with L-asparaginase.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sudden respiratory distress syndrome: Sudden respiratory distress, rapidly progressing to pulmonary edema and cardiomegaly, has been reported with high-dose cytarabine. May present as severe dyspnea with a rapid onset and refractory hypoxia with diffuse pulmonary infiltrates, leading to respiratory failure; may be fatal (Morgan 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumor lysis syndrome: Tumor lysis syndrome and subsequent hyperuricemia may occur; consider antihyperuricemic therapy and hydrate accordingly.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; may be at higher risk for CNS toxicities and dosage adjustments may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with impaired renal function (high dose cytarabine); may be at higher risk for CNS toxicities and dosage adjustments may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information. There have been case reports of fatal cardiomyopathy when high-dose cytarabine was used in combination with cyclophosphamide as a preparation regimen for transplantation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Delayed progressive ascending paralysis has been reported in two children who received combination chemotherapy with IV and intrathecal cytarabine at conventional doses for the treatment of acute myeloid leukemia (was fatal in one patient).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol: Some products may contain benzyl alcohol; do not use products containing benzyl alcohol or products reconstituted with bacteriostatic diluent intrathecally or for high-dose cytarabine regimens. Benzyl alcohol is associated with gasping syndrome in premature infants.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced physician: <b>[US Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician. Due to the potential toxicities, induction treatment with cytarabine should be in a facility with sufficient laboratory and supportive resources. </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; High-dose treatment: High-dose regimens have been associated with GI, CNS, pulmonary, ocular (reversible corneal toxicity and hemorrhagic conjunctivitis; prophylaxis with ophthalmic corticosteroids is recommended) toxicities, and cardiomyopathy. Neurotoxicity associated with high-dose treatment may present as acute cerebellar toxicity (with or without cerebral impairment), personality changes, or may be severe with seizure and/or coma; may be delayed, occurring up to 3 to 8 days after treatment has begun; possibly irreversible. Risk factors for neurotoxicity include cumulative cytarabine dose, prior CNS disease and renal impairment (incidence may be up to 55% in patients with renal impairment); high-dose therapy (&gt;18 g/m<sup>2</sup> per cycle) and age &gt;50 years also increase the risk for cerebellar toxicity (Herzig 1987).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intrathecal safety: When used for intrathecal administration, should not be prepared during the preparation of any other agents. After preparation, store intrathecal medications in an isolated location or container clearly marked with a label identifying as &quot;intrathecal&quot; use only. Delivery of intrathecal medications to the patient should only be with other medications also intended for administration into the central nervous system (Jacobson 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299114\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155970\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13197&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flucytosine: Cytarabine (Conventional) may diminish the therapeutic effect of Flucytosine. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155972\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155985\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects were demonstrated in animal reproduction studies. Limb and ear defects have been noted in case reports of cytarabine exposure during the first trimester of pregnancy. The following have also been noted in the neonate: Pancytopenia, WBC depression, electrolyte abnormalities, prematurity, low birth weight, decreased hematocrit or platelets. Risk to the fetus is decreased if treatment can be avoided during the first trimester; however, women of childbearing potential should be advised of the potential risks.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046766\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Liver function tests, CBC with differential and platelet count, serum creatinine, BUN, serum uric acid; signs of neurotoxicity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155964\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits DNA synthesis. Cytarabine gains entry into cells by a carrier process, and then must be converted to its active compound, aracytidine triphosphate. Cytarabine is a pyrimidine analog and is incorporated into DNA; however, the primary action is inhibition of DNA polymerase resulting in decreased DNA synthesis and repair. The degree of cytotoxicity correlates linearly with incorporation into DNA; therefore, incorporation into the DNA is responsible for drug activity and toxicity. Cytarabine is specific for the S phase of the cell cycle (blocks progression from the G<sub>1</sub> to the S phase). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155981\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Not effective when administered orally; less than 20% absorbed orally </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 3 &plusmn; 11.9 L/kg; total body water; widely and rapidly since it enters the cells readily; crosses blood-brain barrier with CSF levels of 40% to 50% of plasma level </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 13%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Primarily hepatic; metabolized by deoxycytidine kinase and other nucleotide kinases to aracytidine triphosphate (active); about 86% to 96% of dose is metabolized to inactive uracil arabinoside (ARA-U); intrathecal administration results in little conversion to ARA-U due to the low levels of deaminase in the cerebral spinal fluid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: IV: Initial: 7 to 20 minutes; Terminal: 1 to 3 hours; Intrathecal: 2 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: SubQ: 20 to 60 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~80%; 90% as metabolite ARA-U) within 24 hours </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323088\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Cytarabine (PF) Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/mL (5 mL): $7.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/mL (20 mL): $24.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Cytarabine Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/mL (25 mL): $18.41</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155986\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aleksan (UA);</li>\n      <li>Alexan (AE, AT, BG, CH, CL, CZ, DK, EC, GB, HK, HN, HR, HU, ID, IE, IT, JO, LB, MT, PL, PT, QA, RO, RU, SA, SE, SI, SK, TH, TR, VN, ZA);</li>\n      <li>Ara-C (AR);</li>\n      <li>Arabine (DK, FI, FR);</li>\n      <li>Arabitin (JP);</li>\n      <li>Aracytin (CO, GR, IT, UY);</li>\n      <li>Aracytine (FR);</li>\n      <li>Cancyt (PH);</li>\n      <li>Citafam (AR);</li>\n      <li>Citarabina (ES);</li>\n      <li>Cyclocide (TW);</li>\n      <li>Cylocide (JP);</li>\n      <li>Cytabin (BD);</li>\n      <li>Cytarabin (DE, NO);</li>\n      <li>Cytarabine (AU);</li>\n      <li>Cytarabine Injection (AU, GB, NZ);</li>\n      <li>Cytarabinum-Delta West (LU);</li>\n      <li>Cytarine (IN, SG, TH, VN, ZW);</li>\n      <li>Cytonal (RU, TR);</li>\n      <li>Cytosa U (KR);</li>\n      <li>Cytosar (AE, AT, BE, BG, BH, CH, CN, CY, CZ, EE, EG, FI, GB, GH, HK, HN, HR, HU, IL, IQ, IR, JO, KE, KW, LB, LU, LV, LY, NL, OM, PE, PK, PT, QA, RO, SA, SY, TH, TZ, UG, VN, YE, ZM);</li>\n      <li>Cytosar-U (ID, KR, MY, VE);</li>\n      <li>Cytox (PH);</li>\n      <li>Cytrostar (LK);</li>\n      <li>Darbin (BR, PY);</li>\n      <li>Laracit (CO, CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Medsara (MX);</li>\n      <li>Mokcell (PE);</li>\n      <li>Moxell (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Oncotar (LK);</li>\n      <li>Saidewei (CN);</li>\n      <li>Starasid (JP);</li>\n      <li>Tabine (PH);</li>\n      <li>Tarabin (BD);</li>\n      <li>Tsytozar (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Allwood M, Stanley A. <i>The Cytotoxics Handbook</i>. 4th edition. Abingdon: Radcliffe Medical Press; 2003.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amadori S, Arcese W, Isacchi G, et al. Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. <i>J Clin Oncol</i>. 1991;9(7):1210-1214.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/2045861/pubmed\" target=\"_blank\" id=\"2045861\">2045861</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Archimbaud E, Leblond V, Michallet M, et al. Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia. <i>Blood</i>. 1991;77(9):1894-1900.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/2018832/pubmed\" target=\"_blank\" id=\"2018832\">2018832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Archimbaud E, Thomas X, Leblond V, et al. Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial. <i>J Clin Oncol</i>. 1995;13(1):11-18.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/7799010/pubmed\" target=\"_blank\" id=\"7799010\">7799010</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 98, 170.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. <i>J Clin Oncol</i>. 2011;29(31):4189-4198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/21947834/pubmed\" target=\"_blank\" id=\"21947834\">21947834</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bishop JF, Matthews JP, Young GA, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. <i>Blood</i>. 1996;87(5):1710-1717.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/8634416/pubmed\" target=\"_blank\" id=\"8634416\">8634416</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bleyer WA, Coccia PF, Sather HN, et al, &ldquo;Reduction in Central Nervous System Leukemia With a Pharmacokinetically Derived Intrathecal Methotrexate Dosage Regimen,&rdquo; <i>J Clin Oncol</i>, 1983, 1(5):317-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/6366138/pubmed\" target=\"_blank\" id=\"6366138\">6366138</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bowman WP, Shuster JJ, Cook B, et al. Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a pediatric oncology group study. <i>J Clin Oncol</i>. 1996;14(4):1252-1261.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/8648381/pubmed\" target=\"_blank\" id=\"8648381\">8648381</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cairo MS, Gerrard M, Sposto R, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. <i>Blood</i>. 2007;109(7):2736-2743.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/17138821/pubmed\" target=\"_blank\" id=\"17138821\">17138821</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Capizzi RL, Poole M, Cooper MR, et al. Treatment of poor risk acute leukemia with sequential high-dose ARA-C and asparaginase. <i>Blood</i>. 1984;63(3):694-700.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/6696996/pubmed\" target=\"_blank\" id=\"6696996\">6696996</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Capizzi RL, White JC, Powell BL, et al, &ldquo;Effect of Dose on the Pharmacokinetic and Pharmacodynamic Effects of Cytarabine,&rdquo; <i>Semin Hematol</i>, 1991, 28(3 Suppl 4):54-69.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cheung YW, Vishnuvajjala BR, Flora KP. Stability of cytarabine, methotrexate sodium, and hydrocortisone sodium succinate admixtures. <i>Am J Hosp Pharm</i>. 1984;41(9):1802-1806.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/6496516/pubmed\" target=\"_blank\" id=\"6496516\">6496516</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cooper TM, Alonzo TA, Gerbing RB, et al. AAML0523: A report from the Children&rsquo;s Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia. <i>Cancer</i>. 2014 [Epub ahead of print].<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/24771494/pubmed\" target=\"_blank\" id=\"24771494\">24771494</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cooper TM, Franklin J, Gerbing RB, et al. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group. <i>Cancer</i>. 2012;118(3):761-769.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/21766293/pubmed\" target=\"_blank\" id=\"21766293\">21766293</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cytarabine injection [prescribing information]. Bedford, OH: Ben Venue Laboratories, Inc; September 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cytarabine injection [prescribing information]. New York, NY: Pfizer Injectables; December 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cytarabine injection [prescribing information]. Paramus, NJ: Mayne Pharma (USE) Inc; January 2004.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de Lemos ML, Monfared S, Denyssevych T, et al, &ldquo;Evaluation of Osmolality and pH of Various Concentrations of Methotrexate, Cytarabine, and Thiotepa Prepared in Normal Saline, Sterile Water for Injection, and Lactated Ringers&rsquo;s Solution for Intrathecal Administration,&rdquo; <i>J Oncol Pharm Pract</i>, 2009, 15(1):45-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/18772215/pubmed\" target=\"_blank\" id=\"18772215\">18772215</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Holdsworth M, et al. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patient. <i>Pediatr Blood Cancer</i>. 2013;60(7):1073-1082.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/23512831 /pubmed\" target=\"_blank\" id=\"23512831 \">23512831 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Sung L, et al; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/21465637/pubmed\" target=\"_blank\" id=\"21465637\">21465637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Floyd J, Mirza I, Sachs B, et al, &quot;Hepatotoxicity of Chemotherapy,&quot; <i>Semin Oncol</i>, 2006, 33(1):50-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/16473644/pubmed\" target=\"_blank\" id=\"16473644\">16473644</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gamis AS, Alonzo TA, Meshinchi S, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children&rsquo;s Oncology Group trial AAML0531. <i>J Clin Oncol</i>. 2014;32(27):3021-3032.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/25092781/pubmed\" target=\"_blank\" id=\"25092781\">25092781</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gaynon PS, Steinherz PG, Bleyer WA, et al, &ldquo;Improved Therapy for Children With Acute Lymphoblastic Leukemia and Unfavorable Presenting Features: A Follow-Up Report of the Childrens Cancer Group Study CCG-106,&rdquo; <i>J Clin Oncol</i>, 1993, 11(11):2234-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/8229139/pubmed\" target=\"_blank\" id=\"8229139\">8229139</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gibson BE, Webb DK, Howman AJ, et al. Results of a randomized trial in children with acute myeloid leukaemia: medical research council AML12 trial. <i>Br J Haematol</i>. 2011;155(3):366-376.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/21902686/pubmed\" target=\"_blank\" id=\"21902686\">21902686</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goldman S, Smith L, Anderson JR, et al. Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report. <i>Leukemia.</i> 2013;27(5):1174-1177.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/22940833/pubmed\" target=\"_blank\" id=\"22940833\">22940833</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guest EM, Aplenc R, Sung L, et al. Gemtuzumab ozogamicin (GO) in infants with acute myeloid leukenmia (AML) - combined results from the CHildren's Oncology Group (COG) trials. AAML03P1 and AAML0531. <i>Blood</i>. 2014; 124:377.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/21902686/pubmed\" target=\"_blank\" id=\"21902686\">21902686</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Herzig RH, Hines JD, Herzig GP, et al, &ldquo;Cerebellar Toxicity With High-Dose Cytosine Arabinoside,&rdquo; <i>J Clin Oncol</i>, 1987, 5(6):927-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/3585447/pubmed\" target=\"_blank\" id=\"3585447\">3585447</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacobson JO, Polovich M, McNiff KK, et al, &quot;American Society of Clinical Oncology/Oncology Nursing Society Chemotherapy Administration Safety Standards,&quot; <i>J Clin Oncol</i>, 2009, 27(32):5469-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/19786650/pubmed\" target=\"_blank\" id=\"19786650\">19786650</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kerr JZ, Berg S, and Blaney SM, &ldquo;Intrathecal Chemotherapy,&rdquo; <i>Crit Rev Oncol Hematol</i>, 2001, 37(3):227-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/11248578/pubmed\" target=\"_blank\" id=\"11248578\">11248578</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kintzel PE and Dorr RT, &ldquo;Anticancer Drug Renal Toxicity and Elimination: Dosing Guidelines for Altered Renal Function,&rdquo; <i>Cancer Treat Rev</i>, 1995, 21(1):33-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/7859226/pubmed\" target=\"_blank\" id=\"7859226\">7859226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koren G, Beatty K, Seto A, et al, &ldquo;The Effects of Impaired Liver Function on the Elimination of Antineoplastic Agents,&rdquo; <i>Ann Pharmacother</i>, 1992, 26(3):363-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/1554959/pubmed\" target=\"_blank\" id=\"1554959\">1554959</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Land VJ, Shuster JJ, Crist WM, et al, &ldquo;Comparison of Two Schedules of Intermediate-Dose Methotrexate and Cytarabine Consolidation Therapy for Childhood B-Precursor Cell Acute Lymphoblastic Leukemia: A Pediatric Oncology Group Study,&rdquo; <i>J Clin Oncol</i>, 1994, 12(9):1939-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/8083715 /pubmed\" target=\"_blank\" id=\"8083715 \">8083715 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Larsen EC, Devidas M, Chen s, et al. Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: a report from Children's Oncology Group Study AALL0232. <i>J Clin Oncol</i>. 2016;34(20):2380-2388.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/27114587/pubmed\" target=\"_blank\" id=\"27114587\">27114587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lin WY, Liu HC, Yeh TC, et al, &ldquo;Triple Intrathecal Therapy Without Cranial Irradiation for Central Nervous System Preventive Therapy in Childhood Acute Lymphoblastic Leukemia,&rdquo; <i>Pediatr Blood Cancer</i>, 2008, 50(3):523-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/17455314/pubmed\" target=\"_blank\" id=\"17455314\">17455314</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Magrath I, Adde M, Shad A, et al, &quot;Adults and Children With Small Non-Cleaved-Cell Lymphoma Have a Similar Excellent Outcome When Treated With the Same Chemotherapy Regimen,&quot; <i>J Clin Oncol</i>, 1996, 14(3):925-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/8622041/pubmed\" target=\"_blank\" id=\"8622041\">8622041</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Matloub Y, Lindemulder S, Gaynon PS, et al, &ldquo;Intrathecal Triple Therapy Decreases Central Nervous System Relapse but Fails to Improve Event-Free Survival When Compared With Intrathecal Methotrexate: Results of the Children's Cancer Group (CCG) 1952 Study for Standard-Risk Acute Lymphoblastic Leukemia, Reported by the Children's Oncology Group,&rdquo; <i>Blood</i>, 2006, 108(4):1165-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/16609069/pubmed\" target=\"_blank\" id=\"16609069\">16609069</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Montillo M, Mirto S, Petti MC, et al, &quot;Fludarabine, Cytarabine, and G-CSF (FLAG) for the Treatment of Poor Risk Acute Myeloid Leukemia,&quot; <i>Am J Hematol</i>, 1998, 58(2):105-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/9625576/pubmed\" target=\"_blank\" id=\"9625576\">9625576</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morgan C, Tillett T, Braybrooke J, et al, &ldquo;Management of Uncommon Chemotherapy-Induced Emergencies,&rdquo; <i>Lancet Oncol</i>, 2011, 12(8):806-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/21276754/pubmed\" target=\"_blank\" id=\"21276754\">21276754</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patte C, Auperin A, Gerrard M, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. <i>Blood</i>. 2007;109(7):2773-2780.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/17132719/pubmed\" target=\"_blank\" id=\"17132719\">17132719</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patte C, Auperin A, Michon J, et al. The Soci&eacute;t&eacute; Fran&ccedil;aise d'Oncologie P&eacute;diatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. <i>Blood</i>. 2001;97(11):3370-3379.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/11369626/pubmed\" target=\"_blank\" id=\"11369626\">11369626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pease CL, Horton TM, McClain KL, et al, &ldquo;Aseptic Meningitis in a Child After Systemic Treatment With High Dose Cytarabine,&rdquo; <i>Pediatr Infect Dis J</i>, 2001, 20(1):87-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/11176579/pubmed\" target=\"_blank\" id=\"11176579\">11176579</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pieters R, Schrappe M, De Lorenzo P, et al, &ldquo;A Treatment Protocol for Infants Younger Than 1 Year With Acute Lymphoblastic Leukaemia (Interfant-99): An Observational Study and a Multicentre Randomised Trial,&rdquo; <i>Lancet</i>, 2007, 370(9583):240-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/17658395/pubmed\" target=\"_blank\" id=\"17658395\">17658395</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Radeski D, Cull GM, Cain M, et al, &ldquo;Effective Clearance of Ara-U the Major Metabolite of Cytosine Arabinoside (Ara-C) by Hemodialysis in a Patient With Lymphoma and End-Stage Renal Failure,&rdquo; <i>Cancer Chemother Pharmacol</i>, 2011, 67(4):765-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/20532508/pubmed\" target=\"_blank\" id=\"20532508\">20532508</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ribeiro RC, Rivera GK, Hudson M, et al. An intensive re-treatment protocol for children with an isolated CNS relapse of acute lymphoblastic leukemia. <i>J Clin Oncol</i>. 1995;13(2):333-338.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/20532508/pubmed\" target=\"_blank\" id=\"20532508\">20532508</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rivera GK, Hudson MM, Liu Q, et al. Effectiveness of intensified rotational combination chemotherapy for late hematologic relapse of childhood acute lymphoblastic leukemia. <i>Blood</i>. 1996;88(3):831-837.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/8704238/pubmed\" target=\"_blank\" id=\"8704238\">8704238</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roila F, Herrstedt J, Aapro M, et al; ESMO/MASCC Guidelines Working Group. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. <i>Ann Oncol</i>. 2010;21(suppl 5):v232-v243.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/20555089/pubmed\" target=\"_blank\" id=\"20555089\">20555089</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith G, Damon LE, Rugo HS, et al. &ldquo;High-Dose Cytarabine Dose Modification Reduces the Incidence of Neurotoxicity in Patients With Renal Insufficiency,&rdquo; <i>J Clin Oncol</i>, 1997, 15(2): 833-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/9053511/pubmed\" target=\"_blank\" id=\"9053511\">9053511</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Steinherz PG, Redner A, Steinherz L, Meyers P, Tan C, Heller G. Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan-Kettering-New York-II protocol. <i>Cancer</i>. 1993;72(10):3120-3130.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/8221579/pubmed\" target=\"_blank\" id=\"8221579\">8221579</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Termuhlen AM, Smith LM, Perkins SL, et al. Disseminated lymphoblastic lymphoma in children and adolescents: results of the COG A5971 trial: a report from the Children's Oncology Group. <i>Br J Haematol</i>. 2013;162(6):792-801.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/23889312/pubmed\" target=\"_blank\" id=\"23889312\">23889312</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Winick NJ, Smith SD, Shuster J, et al. Treatment of CNS relapse in children with acute lymphoblastic leukemia: A Pediatric Oncology Group study. <i>J Clin Oncol</i>. 1993;11(2):271-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/8426204/pubmed\" target=\"_blank\" id=\"8426204\">8426204</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Woods WG, Ruymann FB, Lampkin BC, et al, &ldquo;The Role of Timing of High-Dose Cytosine Arabinoside Intensification and of Maintenance Therapy in the Treatment of Children With Acute Nonlymphocytic Leukemia,&rdquo; <i>Cancer</i>, 1990, 66(6):1106-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytarabine-pediatric-drug-information/abstract-text/2205352/pubmed\" target=\"_blank\" id=\"2205352\">2205352</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13197 Version 147.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708668\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F155998\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1046767\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1046759\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F155976\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F155961\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1046771\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49130965\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F155991\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1046770\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F156059\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F156055\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F155982\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F155965\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299114\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F155970\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F155972\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F155985\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1046766\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F155964\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F155981\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323088\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F155986\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13197|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">Cytarabine: Drug information</a></li><li><a href=\"topic.htm?path=cytarabine-patient-drug-information\" class=\"drug drug_patient\">Cytarabine: Patient drug information</a></li></ul></div></div>","javascript":null}